-
EP0634935
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP0634935
| EP0634935 - A NOVEL THERAPY FOR TREATING SEPSIS USING A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.07.1997 Database last updated on 27.07.2024 | Most recent event Tooltip | 18.07.1997 | Application deemed to be withdrawn | published on 03.09.1997 [1997/36] | Applicant(s) | For all designated states NORTH SHORE UNIVERSITY HOSPITAL RESEARCH CORPORATION 350 Community Drive Manhasset, NY 11030 / US | [1995/04] | Inventor(s) | 01 /
GOYERT, Sanna, M. 10 Waterside Plaza Apt. 36F New York, NY 10010 / US | [1995/04] | Representative(s) | Schouboe, Anne, et al Plougmann & Vingtoft A/S Sundkrogsgade 9 P.O. Box 831 2100 Copenhagen O / DK | [N/P] |
| Former [1997/02] | Schouboe, Anne, et al Plougmann, Vingtoft & Partners A/S Sankt Annae Plads 11 P.O. Box 3007 DK-1021 Copenhagen K / DK | ||
| Former [1995/04] | Vossius, Volker, Dr. Dr. Volker Vossius, Patentanwaltskanzlei - Rechtsanwaltskanzlei, Holbeinstrasse 5 D-81679 München / DE | Application number, filing date | 93911583.8 | 06.04.1993 | [1995/04] | WO1993US03154 | Priority number, date | US19920863913 | 06.04.1992 Original published format: US 863913 | [1995/04] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO9319772 | Date: | 14.10.1993 | Language: | EN | [1993/25] | Type: | A1 Application with search report | No.: | EP0634935 | Date: | 25.01.1995 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.10.1993 takes the place of the publication of the European patent application. | [1995/04] | Search report(s) | International search report - published on: | US | 14.10.1993 | (Supplementary) European search report - dispatched on: | EP | 13.12.1995 | Classification | IPC: | C07K13/00, A61K37/02 | [1996/03] | CPC: |
C07K14/705 (EP,US);
A61K38/00 (EP,US)
|
| Former IPC [1995/04] | A61K37/02, C07K13/00 | Designated contracting states | AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [1995/04] | Title | German: | EINE NEUARTIGE THERAPIE DES SEPSIS MITTELS EINER LÖSLICHEN FORM DES REKOMBINANTEN CD14 MYELOMONOCYTISCHEN ANTIGENS | [1995/04] | English: | A NOVEL THERAPY FOR TREATING SEPSIS USING A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN | [1995/04] | French: | NOUVELLE THERAPIE PERMETTANT DE TRAITER LA SEPTICEMIE A L'AIDE D'UNE FORME SOLUBLE DE L'ANTIGENE MYELOMONOCYTIQUE CD14 RECOMBINE | [1995/04] | Entry into regional phase | 07.11.1994 | National basic fee paid | 07.11.1994 | Search fee paid | 07.11.1994 | Designation fee(s) paid | 07.11.1994 | Examination fee paid | Examination procedure | 08.11.1993 | Request for preliminary examination filed International Preliminary Examining Authority: US | 07.11.1994 | Examination requested [1995/04] | 01.03.1996 | Request for accelerated examination filed | 28.06.1996 | Despatch of a communication from the examining division (Time limit: M08) | 28.06.1996 | Decision about request for accelerated examination - accepted: Yes | 08.03.1997 | Application deemed to be withdrawn, date of legal effect [1997/36] | 10.04.1997 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [1997/36] | Fees paid | Renewal fee | 06.04.1995 | Renewal fee patent year 03 | 30.04.1996 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 30.04.1997 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO9204908 (IMTOX PRIVATINSTITUT FUER IMMU [DE]) [Y] 1-12 * the whole document *; | [OX] - A. HAZIOT ET AL., "Soluble CD14 inhibits the activation of monocytes induced by LPS.", JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT, NEW YORK, NY, USA, (19920301), vol. 0, no. 10 part C, page 163 [OX] 1-12 * abstract CB201 * | [DY] - G. SMITH ET AL., "Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, WASHINGTON, DC, USA, vol. 82, no. 24, doi:doi:10.1073/pnas.82.24.8404, pages 8404 - 8408, XP002089643 [DY] 1-12 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.82.24.8404 | [A] - C. MALISZEWSKI, "CD14 and immune response to lipopolysaccharide.", SCIENCE, WASHINGTON, DC, USA, (19910524), vol. 252, page 1321 [A] 1-12 * the whole document * | [PA] - H. ZIEGLER-HEITBROCK ET AL., "CD14: Cell surface receptor and differentiation marker.", IMMUNOLOGY TODAY, AMSTERDAM, THE NETHERLANDS, vol. 14, no. 3, doi:doi:10.1016/0167-5699(93)90212-4, pages 121 - 125, XP024347533 [PA] 1-12 * page 124, column L, line 17 - column R, line 33 * DOI: http://dx.doi.org/10.1016/0167-5699(93)90212-4 | [T] - A. HAZIOT ET AL., "Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood.", THE JOURNAL OF IMMUNOLOGY, BALTIMORE, MD, USA, (19940615), vol. 152, no. 12, pages 5868 - 5876, XP002482814 [T] 1-12 * the whole document * | International search | [Y]WO9101639 (SCRIPPS CLINIC RES [US], et al) | [XY] - Nucleic Acids Research, Volume 17(5), issued 1989, K. MATSUURA et al., "Nucleotide and Amino Acid Sequences of the Mouse CD14 Gene", page 2132, entire document. |